Cargando…

Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2

In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased ves...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacondio, D., Nogueira Pinto, H., Coenen, L., Mulder, I. A., Fontijn, R., van het Hof, B., Fung, W. K., Jongejan, A., Kooij, G., Zelcer, N., Rozemuller, A. J., de Vries, H. E., de Wit, N. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684660/
https://www.ncbi.nlm.nih.gov/pubmed/38016947
http://dx.doi.org/10.1038/s41419-023-06316-8
_version_ 1785151453277454336
author Vacondio, D.
Nogueira Pinto, H.
Coenen, L.
Mulder, I. A.
Fontijn, R.
van het Hof, B.
Fung, W. K.
Jongejan, A.
Kooij, G.
Zelcer, N.
Rozemuller, A. J.
de Vries, H. E.
de Wit, N. M.
author_facet Vacondio, D.
Nogueira Pinto, H.
Coenen, L.
Mulder, I. A.
Fontijn, R.
van het Hof, B.
Fung, W. K.
Jongejan, A.
Kooij, G.
Zelcer, N.
Rozemuller, A. J.
de Vries, H. E.
de Wit, N. M.
author_sort Vacondio, D.
collection PubMed
description In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased vessel number, indicating a reactivation of the angiogenic program. The molecular mechanism(s) responsible for BBB dysfunction and angiogenesis in capCAA is still unclear, preventing a full understanding of disease pathophysiology. The Liver X receptor (LXR) family, consisting of LXRα and LXRβ, was reported to inhibit angiogenesis and particularly LXRα was shown to secure BBB stability, suggesting a major role in vascular function. In this study, we unravel the regulatory mechanism exerted by LXRα to preserve BBB integrity in human brain endothelial cells (BECs) and investigate its role during pathological conditions. We report that LXRα ensures BECs identity via constitutive inhibition of the transcription factor SNAI2. Accordingly, deletion of brain endothelial LXRα is associated with impaired DLL4-NOTCH signalling, a critical signalling pathway involved in vessel sprouting. A similar response was observed when BECs were exposed to hypoxia, with concomitant LXRα decrease and SNAI2 increase. In support of our cell-based observations, we report a general increase in vascular SNAI2 in the occipital cortex of AD patients with and without capCAA. Importantly, SNAI2 strongly associated with vascular amyloid-beta deposition and angiopoietin-like 4, a marker for hypoxia. In hypoxic capCAA vessels, the expression of LXRα may decrease leading to an increased expression of SNAI2, and consequently BECs de-differentiation and sprouting. Our findings indicate that LXRα is essential for BECs identity, thereby securing BBB stability and preventing aberrant angiogenesis. These results uncover a novel molecular pathway essential for BBB identity and vascular homeostasis providing new insights on the vascular pathology affecting AD patients. [Image: see text]
format Online
Article
Text
id pubmed-10684660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106846602023-11-30 Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2 Vacondio, D. Nogueira Pinto, H. Coenen, L. Mulder, I. A. Fontijn, R. van het Hof, B. Fung, W. K. Jongejan, A. Kooij, G. Zelcer, N. Rozemuller, A. J. de Vries, H. E. de Wit, N. M. Cell Death Dis Article In Alzheimer’s disease (AD) more than 50% of the patients are affected by capillary cerebral amyloid-angiopathy (capCAA), which is characterized by localized hypoxia, neuro-inflammation and loss of blood-brain barrier (BBB) function. Moreover, AD patients with or without capCAA display increased vessel number, indicating a reactivation of the angiogenic program. The molecular mechanism(s) responsible for BBB dysfunction and angiogenesis in capCAA is still unclear, preventing a full understanding of disease pathophysiology. The Liver X receptor (LXR) family, consisting of LXRα and LXRβ, was reported to inhibit angiogenesis and particularly LXRα was shown to secure BBB stability, suggesting a major role in vascular function. In this study, we unravel the regulatory mechanism exerted by LXRα to preserve BBB integrity in human brain endothelial cells (BECs) and investigate its role during pathological conditions. We report that LXRα ensures BECs identity via constitutive inhibition of the transcription factor SNAI2. Accordingly, deletion of brain endothelial LXRα is associated with impaired DLL4-NOTCH signalling, a critical signalling pathway involved in vessel sprouting. A similar response was observed when BECs were exposed to hypoxia, with concomitant LXRα decrease and SNAI2 increase. In support of our cell-based observations, we report a general increase in vascular SNAI2 in the occipital cortex of AD patients with and without capCAA. Importantly, SNAI2 strongly associated with vascular amyloid-beta deposition and angiopoietin-like 4, a marker for hypoxia. In hypoxic capCAA vessels, the expression of LXRα may decrease leading to an increased expression of SNAI2, and consequently BECs de-differentiation and sprouting. Our findings indicate that LXRα is essential for BECs identity, thereby securing BBB stability and preventing aberrant angiogenesis. These results uncover a novel molecular pathway essential for BBB identity and vascular homeostasis providing new insights on the vascular pathology affecting AD patients. [Image: see text] Nature Publishing Group UK 2023-11-28 /pmc/articles/PMC10684660/ /pubmed/38016947 http://dx.doi.org/10.1038/s41419-023-06316-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Vacondio, D.
Nogueira Pinto, H.
Coenen, L.
Mulder, I. A.
Fontijn, R.
van het Hof, B.
Fung, W. K.
Jongejan, A.
Kooij, G.
Zelcer, N.
Rozemuller, A. J.
de Vries, H. E.
de Wit, N. M.
Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title_full Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title_fullStr Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title_full_unstemmed Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title_short Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
title_sort liver x receptor alpha ensures blood-brain barrier function by suppressing snai2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684660/
https://www.ncbi.nlm.nih.gov/pubmed/38016947
http://dx.doi.org/10.1038/s41419-023-06316-8
work_keys_str_mv AT vacondiod liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT nogueirapintoh liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT coenenl liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT mulderia liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT fontijnr liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT vanhethofb liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT fungwk liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT jongejana liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT kooijg liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT zelcern liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT rozemulleraj liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT devrieshe liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2
AT dewitnm liverxreceptoralphaensuresbloodbrainbarrierfunctionbysuppressingsnai2